Increasing the efficacy of oncolytic adenovirus vectors.
Increasing the efficacy of oncolytic adenovirus vectors.
复制标题
DOI：
10.3390/v2091844
复制
发表时间：
2010-09
期刊：
影响因子：
--
通讯作者：
Wold WSM
中科院分区：
文献类型：
--
作者：
Toth K;Wold WSM
溶瘤腺病毒(Ad)载体为肿瘤治疗提供了一种新的途径。这些载体通过复制和杀死癌细胞来攻击肿瘤。在完成载体复制周期后，受感染的肿瘤细胞裂解并释放能够感染邻近肿瘤细胞的子代病毒粒子。反复的载体复制和细胞裂解循环可以摧毁肿瘤。已经产生了大量的Ad载体并进行了测试，其中一些已经进入了人体临床试验。2005年，中国FDA批准了第一个用于治疗头颈部癌症的溶瘤Add。溶瘤ADS已被证明是安全的，即使静脉注射高剂量的载体，也没有严重不良反应的报道。当作为单一药物应用时，这些载体显示出温和的抗肿瘤作用；当它们与另一种方法结合时，它们的效果更好。溶瘤ADS的有效性可以通过各种方法来提高，包括载体设计、递送技术和辅助治疗，本文将对此进行讨论。
Oncolytic adenovirus (Ad) vectors present a new modality to treat cancer. These vectors attack tumors via replicating in and killing cancer cells. Upon completion of the vector replication cycle, the infected tumor cell lyses and releases progeny virions that are capable of infecting neighboring tumor cells. Repeated cycles of vector replication and cell lysis can destroy the tumor. Numerous Ad vectors have been generated and tested, some of them reaching human clinical trials. In 2005, the first oncolytic Ad was approved for the treatment of head-and-neck cancer by the Chinese FDA. Oncolytic Ads have been proven to be safe, with no serious adverse effects reported even when high doses of the vector were injected intravenously. The vectors demonstrated modest anti-tumor effect when applied as a single agent; their efficacy improved when they were combined with another modality. The efficacy of oncolytic Ads can be improved using various approaches, including vector design, delivery techniques, and ancillary treatment, which will be discussed in this review.